NRG-BR008, The "HERO" Breast Cancer Trial

5 Views
Published
The NRG Oncology Podcast Co-hosts sit with NRG-BR008 "HERO" Study Co-PIs Dr. Lior Braunstein and Dr. Melissa Mitchell to discuss this study for low-risk HER2+ breast cancer. This study will test if HER2-targeted therapy without radiation therapy is as good as the usual treatment of HER2-targeted therapy with radiation for patients with early-stage HER2+ breast cancer.
Category
Oncology
Be the first to comment